Abstract

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.

IPC Classes  ?

• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• C12N 5/09 - Tumour cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/095 - Stem cellsProgenitor cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

Provided are: a method for producing an organoid, the method comprising a step for culturing somatic stem cells in a culture medium containing an agonist of the interferon-γ receptor; and a culture medium for producing an organoid, the culture medium containing an agonist of the interferon-γ receptor.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/074 - Adult stem cells

Abstract

A learning apparatus acquires teaching data including input data. The input data includes an input image and an input text. The input image includes a reference object. The input text relatively designates a target position with reference to the reference object. The apparatus generates output data by inputting the input data to a model. The output data is for specifying the target position. The model includes first and second submodels. The first submodel generates, based on the input image and the input text, a plurality of feature amounts representing the reference object. The plurality of feature amounts have different resolutions from each other. The second submodel generates the output data based on the plurality of feature amounts and the input text. Each of the plurality of feature amounts is input to the second submodel.

IPC Classes  ?

• G06T 7/70 - Determining position or orientation of objects or cameras

Abstract

A moving object control system in the present disclosure performs to acquire an image, acquire a user instruction in a natural language including a relative positional relationship; and predict a region in the image corresponding to a position in a scene indicated by the user instruction based on a fused feature obtained by fusing an image feature indicating a feature of the scene captured in the image, a depth of the scene captured in the image, and a language feature indicating a linguistic feature related to the user instruction by using one or more machine learning models.

IPC Classes  ?

• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• G06T 7/50 - Depth or shape recovery
• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level

Abstract

The present invention is a transmitter that is provided with: an optical comb signal generation unit that generates a first optical comb signal and has a plurality of emission lines arrayed at equal intervals in a frequency range; a modulation unit that modulates the first optical comb signal using a delivery signal to output a second optical comb signal; and a frequency shift unit that is provided with a photonic filter unit that performs filtering so as to impose a prescribed time delay between the emission lines that are adjacent in the second optical comb signal to output a third optical comb signal and a photoelectric conversion unit that, in the third optical comb signal, converts beat signals between the emission lines that are adjacent in the second optical comb signal into electrical signals.

IPC Classes  ?

• H04B 10/50 - Transmitters
• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour

Abstract

The present invention addresses the problem of providing a composition, preparation, pharmaceutical composition, or food containing a bacterial strain capable of inducing beige cells in mammals including humans, and a method for inducing beige cells by administering the bacterial strain. In order to solve the above problem, the present invention provides the following. A composition comprising a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 3, a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 4, a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 14, and a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 30.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention relates to a transcranial magnetic stimulation system and a transcranial magnetic stimulation method. This transcranial magnetic stimulation system comprises: a control device that performs magnetic generation control on a magnetism generation device and performs action control on a robot, these controls being performed in parallel; and a force sensor that is provided at the distal end of an arm part or between the distal end and a coil unit 30. Each time the control device brings the coil unit into contact with a head through action control performed on the robot, the control device performs calibration of the force sensor prior to contact.

IPC Classes  ?

• A61N 2/04 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets using variable fields, e.g. low frequency or pulsating fields

Abstract

An infrared microscope including a light source that emits infrared light of which intensity increases and decreases repetitively, a collecting element that collects the infrared light from the light source, an irradiating side objective element that irradiates the sample with infrared light, a collecting side objective element that collects the infrared light transmitted through the sample, a spectroscopic portion that spectrally processes the collected infrared light, a detector of the infrared light; and a signal processing portion that performs lock-in detection to a detection signal by using a reference signal that synchronizes with an intensity of the infrared light to acquire an infrared spectrum of the sample. The light source has a light-emitting surface having a size of 0.1 μm or greater and 20 μm or less. Light-emitting surface's image is formed on the sample by the collecting element and the irradiating side objective element.

IPC Classes  ?

• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
• G01N 21/55 - Specular reflectivity
• G01N 21/59 - Transmissivity

Abstract

A medical instrument with little risk of clot formation even when blood is flowed therethrough, said medical instrument (1) comprising a plurality of blood channel layers (3), wherein the plurality of blood channel layers (3) each have a plate-shaped main body (5), a groove (9) for forming a blood channel (7), and a resin layer (11) formed on the side wall of the groove (9). A manufacturing method of the medical instrument comprises: a resin applying step for applying a resin to the groove (9) of the plate-shaped main body (5) having the groove (9) for forming the blood channel (7); a bonding step for sandwiching the plate-shaped main body (5) between a first film (41) and a second film (43) and thus bonding the plate-shaped main body (5), the first film (41) and the second film (43); and a post-curing step for, after the bonding step, curing the resin applied to the groove (9) in the resin applying step.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/14 - Dialysis systemsArtificial kidneysBlood oxygenators

Abstract

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Provided are: an agent for organoid formation and proliferation in the absence of an extracellular matrix, the agent including a Hippo signaling pathway inhibitor as an active component; a method for organoid proliferation; an organoid proliferated by the above-described proliferation method; an agent for establishing an organoid in the absence of an extracellular matrix; a method for producing an organoid; an organoid produced by the above-described production method; a regenerative medicine preparation; and a method for screening for an agent that enables culture of an organoid in the absence of an extracellular matrix.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva

Abstract

Provided are a connection device in which flow stagnation does not readily occur, and a method for manufacturing the same. This connection device (1) has an internal cavity (9) for connecting, in a state allowing fluid transport, a flow path (3) and a housing (7) accommodating membranes (5), the connection device (1) also having a plurality of flow path adjustment walls (13) provided in the internal cavity (9). The method for manufacturing the connection device (1) includes a step for installing, in a main body section (11) of the connection device (1), a plurality of virtual flow path layers having thicknesses corresponding to inter-membrane flow paths (17) formed by a plurality of stacked membranes (5), a step for forming the plurality of flow path adjustment walls (13) among the plurality of virtual flow path layers, and a step for obtaining inter-adjustment-wall flow paths (15) formed by the plurality of flow path adjustment walls (13) by forming the plurality of flow path adjustment walls (13) and then removing the virtual flow path layers.

IPC Classes  ?

• A61M 39/10 - Tube connectors or tube couplings

Abstract

Provided is a means to create an animal model that reproduces a state in which an abnormality has occurred in the ocular fundus due to elongation of the eye axis.　An animal model creation method according to the present invention includes a step for inducing myopia in an animal and raising the animal for a specific period of time. The specific period of time is at least 1.5 times the period of time from the induction of myopia to a plateau in reduction of refractive power.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• G01N 33/15 - Medicinal preparations
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

An information processing apparatus acquires an image as input information and uses one or more machine learning models to extract a feature from the input information and to predict a specific region in the image based on the extracted feature. The information processing apparatus outputs a prediction result indicating the specific region including coordinates of a plurality of points surrounding the specific region and information indicating a next point after each of the plurality of points, and trains the one or more machine learning models using a loss function based on a difference between the prediction result including the coordinates of the plurality of points surrounding the specific region and information indicating the next point after each of the plurality of points and ground truth data for the prediction result.

IPC Classes  ?

• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level

Abstract

A medium for culturing a pluripotent stem cell, a pluripotent stem cell culture preparation, and a method for culturing a pluripotent stem cell, and a medium additive for promoting proliferation of a pluripotent stem cell. The medium includes L-tryptophan or a dipeptide in which L-tryptophan and an amino acid are peptide-bonded at a concentration of not less than 176 μM. The dipeptide may include L-alanyl-L-tryptophan.

IPC Classes  ?

• C12N 5/074 - Adult stem cells

Abstract

An eyepiece optical lens includes: a base that has a plurality of faces; a concave portion that forms one face of the base, and is concave in a spherical shape; and a reflection portion that forms a face on an outer peripheral side of the concave portion of the base, the reflection portion reflecting, toward the concave portion, light that has been made incident on the base from a face that is included in the plurality of faces and is different from the concave portion. This provides an eyepiece optical lens that enables a non-invasive analysis of substances contained in aqueous humor of a subject eye.

IPC Classes  ?

• A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
• A61B 3/14 - Arrangements specially adapted for eye photography

Abstract

In the present invention, smooth muscle production molds for forming a main blood vessel part and a branched blood vessel part are prepared. For the main blood vessel part, a smooth muscle layer is formed on a first core rod that has at least one hole, and for the branched blood vessel part, a smooth muscle layer is formed on a surface of a second core rod that has a diameter which enables fitting to the hole of the first core rod. Thereafter, the second core rod having the smooth muscle layer is fitted to the hole of the first core rod, thereby bringing the two smooth muscle layers into contact to form a branched structure, and thus a branched artificial blood vessel model is manufactured. The present invention makes it possible to provide a branched artificial blood vessel model which has a branched blood vessel shape and which constricts and relaxes according to physiological conditions.

IPC Classes  ?

• A61L 27/50 - Materials characterised by their function or physical properties
• A61F 2/06 - Blood vessels
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Abstract

The purpose of the present invention is to provide a new marker that indicates the relevance between a vaccine and the immunity of a subject inoculated with the vaccine. More specifically, the purpose of the present invention is to provide, for example, a method for determining the waning of vaccine effect using a new marker correlated with a tendency of vaccine effect to wane. The problem is solved by providing a method for determining the waning of vaccine effect, the method comprising a step for detecting a mutation in an immunoglobulin heavy-chain region in DNA contained in a sample from a subject, wherein, when the mutation is detected in the immunoglobulin heavy-chain region, the vaccine effect in the subject is determined to have a high tendency to wane.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6872 - Methods for sequencing involving mass spectrometry
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

An antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria is disclosed. The antibacterial composition contains an intestinal bacterium as an active ingredient. Also uses of such composition useful for treating, ameliorating, or preventing an infectious disease or an inflammatory disease, and a pharmaceutical composition containing an intestinal bacterium as an active ingredient are disclosed.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61P 31/04 - Antibacterial agents

Abstract

To provide a device for monitoring a blood flow at the time when the blood flow is stopped using an aortic blockage balloon to thereby prevent complete blockage of the blood flow and prevent outbreak of complications. A balloon catheter device comprising: a balloon catheter including a catheter tube and an aortic blockage balloon provided at a distal end portion of the catheter tube; one or more optical fibers housed in the catheter tube; one or more light irradiation devices disposed in the balloon and coupled to the optical fibers and one or more light detection parts that detect backscattered light of radiated light; and one or more light sources that generate light to be radiated, wherein the balloon catheter device radiates, from the aortic blockage balloon into an aorta, light having a wavelength that can be absorbed by a substance present in blood, detects backscattered light from an inside of a blood vessel, and monitors a state of a blood flow between the aortic blockage balloon and a blood vessel wall over time from intensity of the detected light.

IPC Classes  ?

• A61M 25/10 - Balloon catheters
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

The present invention is to provide a means for enhancing skeletal muscle. According to the present invention, the skeletal muscle is enhanced by using spermidine or a pharmaceutically acceptable salt thereof is administered intramuscularly as an active ingredient.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

An optical repeater comprising: a synthesizing/branching device that branches downlink signal light outputted from a base station into individual downlink signal light outputted to each of a plurality of user terminals, and that synthesizes individual uplink signal light outputted from each of the plurality of user terminals and outputs the synthesized uplink signal light to the base station as uplink signal light; a first optical fiber that transmits power supply light outputted from the base station; and an optical amplification circuit that amplifies any of the uplink signal light, the individual downlink signal light, and the individual uplink signal light by power obtained by photoelectrically converting the power supply light.

IPC Classes  ?

• H04B 10/291 - Repeaters in which processing or amplification is carried out without conversion of the main signal from optical form
• H04B 10/80 - Optical aspects relating to the use of optical transmission for specific applications, not provided for in groups , e.g. optical power feeding or optical transmission through water
• H04B 10/272 - Star-type networks
• H04J 14/02 - Wavelength-division multiplex systems

Abstract

The present invention provides a method for inducing the differentiation of pluripotent stem cells into dopaminergic neural cells or a method for producing a cell group containing dopaminergic neural cells from pluripotent stem cells, each of the methods comprising: (1) bringing the pluripotent stem cells into contact with a TGFβ inhibitor, a BMP inhibitor, and/or a GSK3β inhibitor; and (2) expressing Ascl1 gene in the pluripotent stem cells.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins

Abstract

This pharmaceutical composition is for treating or preventing anti-neutrophil cytoplasmic antibody-associated vasculitis, and contains an anti-IL-33 antibody as an active ingredient. The pharmaceutical composition according to another embodiment is for reducing the need for surgery in endometriosis patients or adenomyosis uteri patients, and contains an IL-33 antagonist as an active ingredient. The pharmaceutical composition according to another embodiment is for treating or preventing endometriosis or adenomyosis uteri, contains an anti-IL-33 antibody as an active ingredient, is administered once every 2 to 8 weeks, and is administered so that the blood trough level of the anti-IL-33 antibody is 6.7 μg/mL or more.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The present invention relates to a pharmaceutical composition for preventing/treating an ocular complication in cGVHD, the composition containing, as an active ingredient, (R)-6-(2-methyl-1,4-diazocan-1-ylsulfonyl)isoquinoline represented by formula (1) or an acid addition salt thereof, or a solvate of the compound or the acid addition salt.

IPC Classes  ?

• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 27/02 - Ophthalmic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Provided is a silk fibroin tubular substance used for reproducing a biological tissue. The silk fibroin tubular substance exhibits a porous makeup at room temperature, the patency rate of the silk fibroin tubular substance when a 1N load is applied thereon in a water-saturated state being 10%-50%.

IPC Classes  ?

• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/56 - Porous or cellular materials
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

What is provided is a therapeutic agent that is effective for the treatment of ovarian clear cell carcinoma. A therapeutic agent for ovarian clear cell carcinoma includes, as an active ingredient, a proteasome inhibitor. Furthermore, in the therapeutic agent for ovarian clear cell carcinoma, the proteasome inhibitor is a substance that reversibly or irreversibly binds to a 20s proteasome-β5 subunit and inhibits a chymotrypsin-like activity. Moreover, in the therapeutic agent for ovarian clear cell carcinoma, the proteasome is a 26s proteasome. In addition, in the therapeutic agent for ovarian clear cell carcinoma, a content proportion of the proteasome inhibitor is 80% by mass or more, 90% by mass or more, or 100% by mass.

IPC Classes  ?

• A61K 31/69 - Boron compounds
• A61K 38/07 - Tetrapeptides
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a simple and highly accurate sample test method, which is capable of being applied to an evaluation of the presence or absence of one or more selected from the group consisting of a gynecological cancer and a precancerous lesion thereof, an evaluation of prognosis of a gynecological cancer patient, or an evaluation of a degree of malignancy of the gynecological cancer, a test kit capable of being used for the test method, and a medicine for treating or preventing a gynecological cancer, which is to be administered to a subject detected by the test method.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

What is provided is a production method for an organoid, including dissociating a biological tissue and carrying out suspension culture of the dissociated biological tissue in a state of being dispersed in a medium to form an organoid, in which the medium is substantially free of a p38 inhibitor and contains the following components (i) to (iv): (i) 0.1% to 10% by volume of an extracellular matrix; (ii) insulin-like growth factor 1 (IGF-1); (iii) fibroblast growth factor 2 (FGF-2); and (iv) at least one selected from the group consisting of a Wnt agonist, a bone morphogenetic protein (BMP) inhibitor, a transforming growth factor-β (TGF-β) inhibitor, and an epidermal growth factor (EGF).

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

[Problem] To provide a sheet or the like that has a less pronounced feeling of use when adhered to skin. [Solution] One aspect of the present invention provides a sheet having an adhesion surface that is used facing skin, said sheet including an elastomer and a light scattering material.

IPC Classes  ?

• C08L 21/00 - Compositions of unspecified rubbers
• A61B 5/25 - Bioelectric electrodes therefor
• B32B 27/00 - Layered products essentially comprising synthetic resin
• B32B 27/18 - Layered products essentially comprising synthetic resin characterised by the use of special additives
• C08K 3/01 - Use of inorganic substances as compounding ingredients characterised by their specific function
• C08K 3/22 - OxidesHydroxides of metals

Abstract

A method of manufacturing an intravascular indwelling device uses a cylindrical holder (1) holding the intravascular indwelling device (20) in an internal space, and an outer cylinder (2) having an inner diameter larger than an outer diameter of the holder (1). The holder (1) holding the intravascular indwelling device (20) is accommodated in the outer cylinder (2), and a suspension(S) of cells of interest are supplied into the outer cylinder (2). The cells of interest are cultured by operating the outer cylinder (2) and the holder (1) such that the suspension(S) flows to the intravascular indwelling device (20) while being in contact with the intravascular indwelling device (20).

IPC Classes  ?

• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

An injection instrument set includes a tubular injection instrument in which an injection liquid is contained, and a guide member disposed on a surface of an injection target of the injection liquid. The injection instrument includes an injection needle which is inserted into the injection target to inject the injection liquid into the injection target. The guide member includes a guide passage which is disposed at a predetermined angle with respect to a surface of the guide member which comes into contact with the injection target and which allows the injection needle to be inserted and guides the injection needle onto the surface of the injection target, and an anti-slip portion disposed at a portion at which the guide member comes into contact with the surface of the injection target.

IPC Classes  ?

• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles

Abstract

The present invention provides: a composition and a food/beverage item which can promote the elongation of pili of an intestinal bacterium and exhibits an anti-bacterial activity; and a method for assisting the examination and diagnosis of a disease caused by a pathogenic bacterium or a pathogenic fungus. The present invention provides a composition containing a bacterium capable of producing 3-phenylpropionic acid (PPA) or 3-(4-hydroxyphenyl)propionic acid (4OHPPA). The present invention also provides a food/beverage item containing PPA or 4OHPPA. The present invention further provides a method for assisting the examination and diagnosis of a disease caused by a pathogenic bacterium or a pathogenic fungus. The method comprises: quantifying the amount of PPA or the amount of 4OHPPA in feces from a subject by using 2-nitrophenylhydrazine; and comparing a value obtained by the quantification of the amount of PPA or the amount of 4OHPPA with a reference value. When the value obtained by the quantification of the amount of PPA or the amount of 4OHPPA is smaller than the reference value, it is determined that the subject is possibly affected by the disease.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/88 - Lyases (4.)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present disclosure provides a method capable of more conveniently determining at an earlier stage whether a cell population collected from a vertebrate animal adipose tissue has mesenchymal stem cells (ASCs) at high purity, a kit for determining it, etc. The present disclosure includes, for example, a method for determining whether a cell population derived from an adipose tissue collected from a vertebrate animal comprises mesenchymal stem cells (ASCs) at high purity, the method comprising detecting expression of one or more genes in the cell population.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

A cell population including macrophages that are CD11b positive, F4/80 positive, CD180 positive, and CD9 positive and that are derived from a tissue selected from the group consisting of placenta, umbilical cord, and amnion with a percentage of 75% or more, the cell population having cell viability of 80% or more.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention provides T cells that express a recombinant receptor and satisfying conditions (I) and (II).　(I) T cells having reduced or eliminated expression and/or function of the PRDM1 gene (II) T cells having reduced or eliminated expression and/or function of the RCOR1 gene, and/or increased or activated expression of the c-Jun gene

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/13 - Immunoglobulins

Abstract

A tactile feedback apparatus includes a pressable portion on which a pressing action is performed by a pressing portion, a detection unit that detects an external force acting on the pressable portion or detects a position of the pressing portion with respect to the pressable portion, a vibration actuator that applies vibration to the pressing portion, a storage unit that stores waveform information for driving the vibration actuator so as to provide the pressing portion with a specific tactile sensation, and a control unit that causes the vibration actuator to vibrate based on the waveform information at a specific point in time in the pressing action. The specific point in time is based on the external force or the position detected by the detection unit.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

[Problem] To easily measure intestinal metabolites. [Solution] This quantification method for quantifying a substance contained in a biological specimen includes a step A for preparing a mixed specimen in which a prescribed amount of the aforementioned substance is mixed with a liquid containing an extract obtained by extracting two or more substances including the aforementioned substance from the specimen, a step B for drying and derivatizing the extract and the mixed specimen by the same method to obtain a derivatized substance group, and a step C for detecting the derivatized substance group obtained in step B by using a mass spectrometer.

IPC Classes  ?

• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
• G01N 30/06 - Preparation

Abstract

Provided is a method of producing a gene-modified T cell population, including mixing a cell population containing T cells with beads each having bound thereto a virus containing a target gene to introduce the target gene into each of the cells of the cell population, wherein the cell population containing the T cells is cultured in a solution containing a CD3 signal activator that is present without being immobilized on a solid phase.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 15/86 - Viral vectors

Abstract

A method for manufacturing a collectively molded multi-optical transmission sheet assembly (100) provided with a collectively molded multi-optical transmission sheet (10) and an accommodation member (20), the method comprising: capturing an image of a position reference portion (25) provided in the accommodation member (20); generating a template image (I) that includes a reference position marker (I1) corresponding to the position reference portion (25) and a core position marker (I2) indicating the ideal position of each of core regions (11) with respect to the position reference portion (25) and that is superimposed such that the reference position marker (I1) and the captured image of the position reference portion (25) match; accommodating one end of the collectively molded multi-optical transmission sheet (10) in a disposition hole (23) of the accommodation member (20); capturing images of the core regions (11) exposed on an end surface at the one end accommodated in the disposition hole (23); adjusting the relative position of the collectively molded multi-optical transmission sheet (10) with respect to the accommodation member (20) such that the respective positions of the captured images of the core regions (11) and the respective positions of the core position markers (I2) corresponding to the respective positions match; and securing the collectively molded multi-optional transmission sheet (10) to the accommodation member (20).

IPC Classes  ?

• G02B 6/36 - Mechanical coupling means
• G02B 6/32 - Optical coupling means having lens focusing means
• G02B 6/42 - Coupling light guides with opto-electronic elements

Abstract

A method for manufacturing an integrally molded multi-light-transmission sheet assembly (100A) comprising an integrally molded multi-light-transmission sheet (10) and an accommodation member (20), wherein: a position reference section (25) and a reference structure (R) are imaged, the position reference section (25) being provided to the accommodation member (20), and the reference structure (R) including a reference position marker (R1) that corresponds to the position reference section (25) and core position markers (R2) that indicate individual ideal positions for core regions (11) with reference to the position reference section (25); an adjusted image is generated in which an image of the reference position marker (R1) and an image of the position reference section (25) are overlaid so as to coincide with each other; one end portion of the integrally molded multi-light-transmission sheet (10) is accommodated in a disposition hole (23) in the accommodation member (20); core regions (11) exposed on the end surface at the one end portion accommodated in the disposition hole (23) are imaged; the position of the integrally molded multi-light-transmission sheet (10) relative to the accommodation member (20) is adjusted such that the positions of images of the imaged core regions (11) and the positions of core position markers (R2) corresponding to the positions of the images coincide with each other; and the integrally molded multi-light-transmission sheet (10) is fixed to the accommodation member (20).

IPC Classes  ?

• G02B 6/36 - Mechanical coupling means
• G02B 6/32 - Optical coupling means having lens focusing means
• G02B 6/42 - Coupling light guides with opto-electronic elements

Abstract

An optical waveguide device includes a substrate, a first waveguide disposed on or in the substrate, and a second waveguide disposed on a first surface of the substrate, wherein the second waveguide includes a core and a cladding covering the core, wherein throughout an entirety of a predetermined region, a portion of the core overlaps the first waveguide when viewed from a direction normal to the first surface, in wherein the predetermined region, the core has a bottom surface in contact with the first surface and a convex surface connected to the bottom surface, and wherein the core includes a portion whose thickness gradually decreases from a widthwise center to widthwise ends in a transverse cross-sectional view.

IPC Classes  ?

• G02B 6/26 - Optical coupling means
• G02B 6/02 - Optical fibres with cladding

Abstract

This cryotherapy device comprises a head part, a cooling mechanism, and a control unit. The head part has a probe that forms a working surface to be brought close to or into contact with the surface of a skin to be treated. The cooling mechanism cools the probe. The control unit controls the cooling mechanism such that the probe is maintained at a target temperature of 0°C or lower. The probe is configured so as to freeze the tissue of the skin through the working surface and thereby selectively induce the apoptosis of diseased cells including at least nevus cells.

IPC Classes  ?

• A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques

Abstract

Provided is a method for acquiring data on the efficacy of a CDK4/6 inhibitor in lung cancer cells, the method comprising detecting an EGFR gene mutation and a CDKN2A/B gene deletion or loss-of-function mutation in lung cancer cells derived from a lung cancer patient. The presence of an EGFR gene mutation and a CDKN2A/B gene deletion or loss-of-function mutation indicates the efficacy of the CDK4/6 inhibitor.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a recovery assistance device, a recovery assistance system, and a storage medium. This recovery assistance device (22) comprises at least: an information acquisition unit (50) that acquires biological information relating to the physical function of a subject and treatment information including a plurality of treatment method candidates; a curve generation unit (52) that uses the acquired biological information and treatment information to generate, for each treatment method candidate, a prognosis prediction curve (94) indicating the prediction result of the degree of recovery of the physical function relative to elapsed time from a reference time point; and a display instruction unit 62 that instructs a display means (26) to compare and display the prognosis prediction curve (94) for each of the generated treatment method candidates.

IPC Classes  ?

• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising

Abstract

A bone conduction hearing-aid system includes an intracorporeal unit that is embedded under a scalp and that includes an intracorporeal vibration generator configured to generate vibration by receiving a magnetic field frequency, and an extracorporeal unit that is disposed extracorporeally, that is configured to generate the magnetic field frequency and to apply the magnetic field frequency to the intracorporeal unit, and that is configured to generate vibration by an extracorporeal vibration generator. The vibration generated by the intracorporeal unit and the vibration generated by the extracorporeal unit vibrate a skull.

IPC Classes  ?

• H04R 25/00 - Deaf-aid sets

Abstract

A bone conduction hearing-aid unit embedded under a scalp. The bone conduction hearing-aid unit includes a vibration generator configured to generate vibration, and an anchor. A magnetic field frequency is applied to the vibration generator from the outside of the scalp to generate vibration. The vibration is transmitted to a skull via the anchor.

IPC Classes  ?

• H04R 25/00 - Deaf-aid sets

Abstract

The purpose of the present invention is to provide: an agent that is for treating tendon disorders using platelets produced from an adipose tissue-derived mesenchymal stem cell line (ASCL), and that has a stable and excellent therapeutic effect on tendon disorders; and the like.　The present invention encompasses: an agent that is for treating tendon disorder, and that comprises, as an active ingredient, platelets produced by a production method having the following steps (A)-(C); and the like. (A) A step for inducing differentiation, into mature adipocytes, of at least one type of cells selected from stromal vascular cell groups including mesenchymal stem cells, adipocyte progenitor cells, and stromal cells in adipose tissues of a vertebrate; (B) a step for inducing dedifferentiation of the mature adipocytes obtained in step (A) to obtain an adipose tissue-derived mesenchymal stem cell line of the vertebrate; and (C) a step for culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a culture liquid for inducing differentiation into megakaryocytic cells and that contains iron ions and iron transporters, and collecting platelets from a culture product.

IPC Classes  ?

• A61K 35/19 - PlateletsMegacaryocytes
• A61P 19/00 - Drugs for skeletal disorders
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07K 14/62 - Insulins
• C07K 14/79 - Transferrins, e.g. lactoferrins, ovotransferrins
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 9/50 - Proteinases
• C12N 9/66 - Elastase
• C12N 9/76 - TrypsinChymotrypsin

Abstract

A bone conduction hearing-aid unit that is entirely embedded under a scalp. The bone conduction hearing-aid unit includes a vibration generating device configured to generate vibration, and an anchor fixed to a skull and configured to transmit the vibration to the skull. The vibration generating device is detachably fixed to the anchor.

IPC Classes  ?

• H04R 25/00 - Deaf-aid sets

Abstract

Disclosed is a method for evaluating cell differentiation state, including inducing pluripotent stem cells to differentiate into mesodermal cells in a liquid medium by a first differentiation treatment for inducing pluripotent stem cells to differentiate into mesodermal cells and a second differentiation treatment for inducing the mesodermal cells to differentiate into cardiomyocytes; collecting a supernatant of the liquid medium comprising cells induced to differentiate by the second differentiation treatment; and measuring miRNA-3p in miR-1/133a cluster in the supernatant, where the miRNA-3p is at least one selected from a group consisting of miR-1-3p and miR-133a-3p, and the measured value of miRNA-3p is an index of differentiation into cardiomyocytes.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention monitors whether an exercise prescription (for example, exercise amount, exercise intensity, and exercise frequency) presented by a doctor is being followed even outside of a hospital, and supports the exercise. A server 1 supports rehabilitation for a disease and comprises a patient information acquisition unit 51 and a patient information presentation unit 53. The patient information acquisition unit 51 acquires the value of a first index (the number of steps or the like) of exercise amount and the value of a second index (a heart rate or the like) of exercise intensity with respect to a predetermined exercise imposed on the patient as rehabilitation for the disease. The patient information presentation unit 53 presents, as support information for supporting rehabilitation for the disease, the number of steps for achieving a target heart rate of the patient including a combination of the acquired number of steps and heart rate (for example, the number of steps walked at a heart rate of 100 bpm or more).

IPC Classes  ?

• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance

Abstract

The purpose of the present invention is to provide a novel therapeutic agent or prophylactic agent for dry eye, a therapeutic agent or prophylactic agent for a graft-versus-host disease, a corneal epithelial wound healing promoter, an inflammatory cell inhibitor that infiltrates the cornea, a tear fluid amount retaining agent, a corneal epithelial disorder inhibitor, a cell proliferation marker-positive cell inhibitor, and an inhibitor of lymphocyte differentiation into effector T cells. The present invention provides the following, each of which contains, as an active ingredient, a substance derived from a culture supernatant of stem cells: a therapeutic agent or prophylactic agent for dry eye; a therapeutic agent or prophylactic agent for a graft-versus-host disease; a corneal epithelial wound healing promoter; an inflammatory cell inhibitor infiltrating into the cornea; a tear fluid amount retaining agent; a corneal epithelial disorder inhibitor; a cell proliferation marker-positive cell inhibitor; or an inhibitor of lymphocyte differentiation into effector T cells.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61P 27/04 - Artificial tearsIrrigation solutions
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Provided are a phthalocyanine dye represented by formula (1) and a method for producing the same. (In the formula, M, L, Q, R2, R3, R7, R8, R4, R5, R6, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, X2, and X3 are as defined in the claims.)

IPC Classes  ?

• C09B 47/04 - Phthalocyanines
• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 31/695 - Silicon compounds
• A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A spintronics device is a spintronics device that generates a spin current, the device including: a metal layer; a semiconductor layer having a lower carrier mobility or a lower electrical conductivity than the metal layer; and a gradient layer located at a boundary between the metal layer and the semiconductor layer, and having a gradient in the carrier mobility or the electrical conductivity.

IPC Classes  ?

• H10N 50/85 - Materials of the active region
• H01F 10/32 - Spin-exchange-coupled multilayers, e.g. nanostructured superlattices
• H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices
• H10N 50/01 - Manufacture or treatment
• H10N 50/10 - Magnetoresistive devices

Abstract

An object of the present invention is to provide further assistance in addition to assistance by tactile force transmission. An information presentation system includes a master device to which an operation by an operator is input and a slave device that operates in accordance with the operation input to the master device. Furthermore, the information presentation system includes a tactile force transmission unit, a calculation unit, and a presentation unit. The tactile force transmission unit controls tactile force transmission in the master device and the slave device. The calculation unit calculates physical characteristics of a substance in contact with the slave device on the basis of an external force input from the environment to the slave device while the slave device maintains a predetermined motion state. The presentation unit presents the physical characteristics of the substance calculated by the calculation unit.

IPC Classes  ?

• B25J 3/00 - Manipulators of leader-follower type, i.e. both controlling unit and controlled unit perform corresponding spatial movements
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

An information processing device (10) according to an embodiment includes a determination unit (102) that generates a determination result in which the mental state of a subject is determined by inputting pulsation information relating to the heartbeat of the subject and body motion information relating to body motion of the subject to a trained model. The trained model has been trained using, for a plurality of providers that provide training data, pulsation information relating to heartbeat of the providers, body motion information relating to body motion of the providers, and index information relating to specific mental tendencies of the providers.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/33 - Heart-related electrical modalities, e.g. electrocardiography [ECG] specially adapted for cooperation with other devices
• A61B 5/332 - Portable devices specially adapted therefor
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

[Problem] To more appropriately support diagnosis when diagnosis accompanied by a medical action from a remote place is performed. [Solution] A remote medical support system 1 comprises a work mechanism 25, an operation mechanism 15, an operation control unit 313, and a presentation unit 314. The work mechanism 25 is a mechanism for performing a medical action including palpation of a subject. The operation mechanism 15 is a mechanism for receiving a remote operation for the work mechanism 25 from an operator. The operation control unit 313 controls the operation of the work mechanism 25 according to the remote operation received by the operation mechanism 15, and transmits the reaction force applied to the work mechanism 25 in response to the contact of the work mechanism 25 with the subject to the operator via the operation mechanism 15 as a tactile force. The presentation unit 314 presents, to the operator, support information for supporting diagnosis based on the medical practice acquired on the work mechanism side.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• B25J 3/00 - Manipulators of leader-follower type, i.e. both controlling unit and controlled unit perform corresponding spatial movements

Abstract

An optical coupling circuit device includes an optical circuit board including an optical circuit; an optical fiber coupled to the board; and an optical coupling waveguide formed in the board and configured to optically couple the fiber and the optical circuit. The fiber includes a cut surface obliquely cut at 3° to 30° to an optical axis of the fiber, and is coupled to the board at the cut surface. With a direction normal to the board being z-direction, a plane orthogonal to z-direction being xy-plane, a direction in which an optical axis of the optical coupling waveguide extends toward the fiber in xy-plane being x-direction, and a direction orthogonal to x-direction and z-direction being y-direction, second position of a leading end of a core end surface exposed at the cut surface is offset from first position of a coupling end of the optical coupling waveguide in x-direction and z-direction.

IPC Classes  ?

• G02B 6/30 - Optical coupling means for use between fibre and thin-film device

Abstract

The present invention comprises a depression symptom determination unit 13 for determining a depression symptom of a subject, who is subject to determination, by inputting a feature vector generated on the basis of a feature amount of a conversation carried out by the subject to a machine-learned determination model, the determination being performed by the determination model, which is generated by machine learning using, as training data, conversation data for subjects satisfying prescribed extraction conditions and exclusion conditions relating to depression symptoms. By using, as an exclusion condition, a condition that subjects diagnosed with manic depression and subjects for whom a prescribed manic depression evaluation scale score is equal to or greater than a manic depression threshold value are excluded, it becomes possible to perform machine learning of the determination model without being affected by conversation data for when a manic depression patient is temporarily in a depressed state or a manic state, and it becomes possible to determine a depression symptom of the subject in a state of having the depression symptom as a personal characteristic of the subject instead of as a temporary state.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention is provided with a depression symptom determination unit 13 for determining a depression symptom of a subject who is the subject of determination by inputting a feature vector generated on the basis of a feature amount of an interview with the subject into a machine-learned determination model. The determination is performed by the determination model generated by machine learning using, as learning data, interview data from subjects satisfying a predetermined extraction condition and exclusion condition regarding depression symptoms. The extraction condition is set on the basis of the result of a doctor diagnosis, while positive example/negative example labels are assigned to the learning data on the basis of the HAMD scores. Thus, it becomes possible, even for a subject who is temporarily in a state different from the result of a doctor diagnosis of a depression symptom, to determine a depression symptom according to the state of the subject during the interview.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

An object of the present invention is to make control for friction compensation executed in a master-slave system more appropriate. A control system includes a master device, a slave device, and a control device. Furthermore, the control device includes a friction compensation control unit and a tactile force transmission unit. The friction compensation control unit calculates a force for assisting an operation in the master device with respect to friction generated in the slave device on the basis of a moving average of velocity of a movable portion in the slave device. The tactile force transmission unit assists the operation in the master device with a force calculated by the friction compensation control unit and controls tactile force transmission in the master device and the slave device.

IPC Classes  ?

• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61B 18/14 - Probes or electrodes therefor
• A61B 34/37 - Leader-follower robots
• B25J 9/16 - Programme controls
• B25J 13/02 - Hand grip control means
• G05B 15/02 - Systems controlled by a computer electric
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 34/30 - Surgical robots

Abstract

This learning device, which performs machine learning, includes: an acquiring unit that acquires teacher data including input data and correct answer data, the input data including an input image including a reference object and input text that relatively specifies a target position by referring to the reference object; a generating unit that inputs the input data into a model to generate output data for specifying the target position, a reference position that is the position of the reference object, and a positional relationship of the target position with respect to the reference position; and an updating unit that updates a parameter of the model such that a loss obtained by inputting the output data and the correct answer data into a loss function decreases. The loss function is based on at least two of: a first error between the target position specified by the output data and the target position specified by the correct answer data; a second error between the reference position specified by the output data and the reference position specified by the correct answer data; and a third error between the positional relation specified by the output data and the positional relation specified by the correct answer data.

IPC Classes  ?

• G06N 20/00 - Machine learning
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 3/09 - Supervised learning

Abstract

A learning apparatus for performing machine learning includes an acquisition unit configured to acquire teaching data including input data and correct answer data, the input data including an input image that contains a reference object and an input text that relatively designates a target position by referring to the reference object; a generation unit configured to input the input data to a model to generate output data for specifying the target position, a reference position that is a position of the reference object, and a positional relationship of the target position with respect to the reference position; and an update unit configured to update a parameter of the model to reduce a loss obtained by inputting the output data and the correct answer data to a loss function. The loss function is based on at least two errors of a first error between the target position specified by the output data and the target position specified by the correct answer data, a second error between the reference position specified by the output data and the reference position specified by the correct answer data, and a third error between the positional relationship specified by the output data and the positional relationship specified by the correct answer data.

IPC Classes  ?

• G06V 20/58 - Recognition of moving objects or obstacles, e.g. vehicles or pedestriansRecognition of traffic objects, e.g. traffic signs, traffic lights or roads
• G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level

Abstract

A feature amount extractor extracts a feature amount representing the feature of a brain wave from the brain wave of a subject, the brain wave being measured when a magnetic stimulation is applied to the brain of the subject. A mental disorder determiner determines whether or not the subject has a predetermined mental disorder on the basis of a feature amount variation that is a differential value between a feature amount extracted from a brain wave measured immediately before the magnetic stimulation and a feature amount extracted from a brain wave measured immediately after the magnetic stimulation.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/256 - Wearable electrodes, e.g. having straps or bands
• A61B 5/273 - Connection of cords, cables or leads to electrodes
• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/384 - Recording apparatus or displays specially adapted therefor
• A61B 5/386 - Accessories or supplementary instruments therefor

Abstract

An object of the present invention is to provide, for example, a therapeutic agent using a specific mesenchymal stem cell line derived from an adipose tissue (ASCL), the therapeutic agent (i) stably having an excellent therapeutic effect on one or more diseases selected from knee osteoarthritis, traumatic cartilage defect, and osteochondritis dissecans, (ii) loading less physical burden on a patient, (iii) requiring no restriction on patient's hospital visit management, and (iv) having no restriction on the number of treatments. A feature of the present invention is to use a mesenchymal stem cell line derived from an adipose tissue, the mesenchymal stem cell line being produced by a production method comprising: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction of a vertebrate animal adipose tissue comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate animal adipose tissue.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

A composition for decomposition of trypsin or TMPRSS2 containing, as an active ingredient, bacteria that have 00502 protein, or a protein having 30% or higher sequence identity with an amino acid sequence of the 00502 protein and having a trypsin-binding ability; or bacteria that have 00509 protein, or a protein having 30% or higher sequence identity with an amino acid sequence of the 00509 protein and having a trypsin-binding ability.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

One aspect of the present disclosure relates to a conversion device including an acquisition unit configured to acquire a first bit string having a first bit length L1; a conversion unit configured to convert, in accordance with conversion information that associates respective bit strings each having the first bit length L1 with bit strings each having a second bit length L2 uniquely assigned to the respective bit strings, the first bit string into a second bit string having the second bit length L2. The conversion information is created by searching for a clique that includes 2L1 or more nodes, from a graph including nodes and an edge representing the bit strings each having the second bit length L2 that satisfy a predetermined constraint condition.

IPC Classes  ?

• H03M 7/40 - Conversion to or from variable length codes, e.g. Shannon-Fano code, Huffman code, Morse code
• H03M 7/46 - Conversion to or from run-length codes, i.e. by representing the number of consecutive digits, or groups of digits, of the same kind by a code word and a digit indicative of that kind

Abstract

Provided is a cardiomyocyte group comprising cardiomyocytes differentiated from human pluripotent stem cells, the cardiomyocyte group having the following features (1), (2) and (3): (1) comprising myocardial troponin T-positive cells at 90% or more; (2) having spontaneous pulsation of 0-60 times/min; and (3) being within 30 days after differentiation has started. Also provided is a pharmaceutical composition comprising: said cardiomyocyte group and/or a myocardial sphere in which said cardiomyocyte group has been spheroidized; and a pharmaceutically acceptable carrier. Further provided is a method for producing a cardiomyocyte group, the method comprising: (a) a step for performing expansion culture of human pluripotent stem cells; (b) a step for culturing the human pluripotent stem cells resulting from the expansion culture, under a condition that allows the cells to differentiate into cardiomyocytes to produce a cell group containing 60% or more of cardiomyocytes; and (c) a step for removing human pluripotent stem cells and non-cardiomyocytes from the cell group.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

[Problem] To more appropriately grasp the situation of a treatment in a medical procedure. [Solution] This medical device 1 comprises a slave-side actuator 212, an operation control unit 311, a state specification unit 313, and a situation determination unit 314. The slave-side actuator 212 causes a treatment mechanism 60 to perform a treatment on a patient. The operation control unit 311 calculates a control parameter relating to a force-tactile sensation on the basis of information relating to a position detected in the course of the treatment and controls the operation of the slave-side actuator 212 on the basis of the control parameter. The state specification unit 313 calculates a state parameter indicating the state of a treatment target site 40 with which the treatment mechanism 60 is in contact on the basis of the information relating to the position detected in the course of the treatment. The situation determination unit 314 performs a determination based on the control parameter and the state parameter, and thereby detects when the treatment by the treatment mechanism 60 has reached a prescribed situation.

IPC Classes  ?

• A61B 17/16 - Instruments for performing osteoclasisDrills or chisels for bonesTrepans

Abstract

Provided is a primer set for the detection of a carbapenemase-producing Enterobacteriaceae bacterium, the primer set comprising: at least one LAMP primer set that is specific to each of carbapenemase genes, i.e., bla NDM type, bla OXA-type, bla IMP type, bla KPC type and bla VIM type, among various bacterial types of carbapenemase-producing Enterobacteriaceae bacteria; or at least one LAMP DNA chromatography primer set.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins

Abstract

An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: [In the formulas, each of formula (III) and formula (IV) represents an α-anomer or a β-anomer; each of R1, R3, and R4 is —OH or —OAc; R2 is a halogen atom, —OH, or —OAc; and R5 is —CH3, —C≡CH, —C≡CCH3, or —CH2C≡CH.]

IPC Classes  ?

• A61K 31/7024 - Esters of saccharides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

This nanocarbon light source element is provided with: a nanocarbon light source disposed on a substrate; and a wavelength selection structure that is provided to the nanocarbon light source and that selects a specific wavelength. Light of the specific wavelength is emitted through the wavelength selection structure. A multi-wavelength nanocarbon light source array according to the present invention is provided with: nanocarbon light sources disposed in an array pattern on a substrate; and wavelength selection structures that are respectively provided to the plurality of nanocarbon light sources and that select different wavelengths. Light of the plurality of wavelengths is emitted through the wavelength selection structures.

IPC Classes  ?

• H01K 1/06 - Carbon bodies
• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
• G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water

Abstract

This sugar intake/metabolism/reward inhibiting agent having lactic acid bacteria as an active ingredient is useful for controlling sugar palatability.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs

Abstract

This thermal detector includes a recess provided on a substrate, a nanocarbon material layer cross-linked to the recess, a temperature-dependent resistance change material layer supported by the nanocarbon material layer, and a pair of electrodes connected to at least one of the resistance change material layer and the nanocarbon material layer.

IPC Classes  ?

• G01J 1/02 - Photometry, e.g. photographic exposure meter Details
• H01L 21/822 - Manufacture or treatment of devices consisting of a plurality of solid state components or integrated circuits formed in, or on, a common substrate with subsequent division of the substrate into plural individual devices to produce devices, e.g. integrated circuits, each consisting of a plurality of components the substrate being a semiconductor, using silicon technology
• H01L 27/04 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being a semiconductor body
• H10N 15/00 - Thermoelectric devices without a junction of dissimilar materialsThermomagnetic devices, e.g. using the Nernst-Ettingshausen effect

Abstract

In the present invention, an infrared spectroscopy chip comprises: a first substrate; a second substrate that faces the first substrate; a flow path that is provided between the first substrate and the second substrate; and one or more nanocarbon light sources that are thermally insulated from the flow path and that irradiate the flow path with infrared light.

IPC Classes  ?

• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
• G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
• H01K 1/06 - Carbon bodies

Abstract

In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being highly efficient. Many attempts have been made, including a stepwise differentiation induction method based on the control of culture conditions or the addition of, for example, various cell growth factors/differentiation factors to a culture solution, but the use of complicated culture steps is a big problem. A method of inducing differentiation into a desired cell type within a short period of time and with high efficiency by use of a pluripotent stem cell that actively undergoes cell differentiation, which is obtained by reducing an undifferentiated state of the pluripotent stem cell, has been developed, and thus the present invention has been completed.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0793 - Neurons
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A therapeutic agent for small cell lung cancer containing an insulin-like growth factor 1 receptor (IGF1R) inhibitor as an active ingredient, and a method for determining whether or not an administration of the therapeutic agent for small cell lung cancer patients is effective, including: detecting the expression of YAP1 or its downstream factors in the cancer cells from the small cell lung cancer patient; and when the expression level of YAP1 or the expression level of the downstream factor of YAP1 is significantly higher than that of a control, it indicates an administration of the therapeutic agent is effective in treating the patient.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/09 - Tumour cells

Abstract

An information processing apparatus in embodiments performs at least one trained machine learning model that includes an encoder and a decoder. The encoder receives inputs of text information including designation of a place, a first image that is an image captured by an image capturing apparatus and that includes the place, and a second image obtained by dividing a region for every identical object in the first image, and outputs tri-modal features that have been generated to include visual features of the first image that has been captured, visual features of the second image obtained by dividing the region, and language features of the text information. The decoder outputs a region on the first image corresponding to the designation of the place in the text information, by using the tri-modal features.

IPC Classes  ?

• G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
• G06T 7/11 - Region-based segmentation
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding
• G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations
• G10L 15/02 - Feature extraction for speech recognitionSelection of recognition unit
• G10L 15/16 - Speech classification or search using artificial neural networks
• G10L 15/22 - Procedures used during a speech recognition process, e.g. man-machine dialog

Abstract

This optical amplifier comprises a substrate, a first optical waveguide that is formed on the substrate, a semiconductor carbon nanotube layer that covers a prescribed region of the first optical waveguide, and an excitation configuration that excites the semiconductor carbon nanotube layer. The optical amplifier amplifies signal light by using an excitation state of electrons of the semiconductor carbon nanotube layer and stimulated emission resulting from incidence of the signal light on the prescribed region.

IPC Classes  ?

• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
• G01J 1/02 - Photometry, e.g. photographic exposure meter Details
• H01S 3/17 - Solid materials amorphous, e.g. glass
• H01S 5/30 - Structure or shape of the active regionMaterials used for the active region
• H10N 15/00 - Thermoelectric devices without a junction of dissimilar materialsThermomagnetic devices, e.g. using the Nernst-Ettingshausen effect

Abstract

According to the embodiments, an information processing device comprises one or more processors that execute one or more trained machine learning models. The one or more trained machine learning models include an encoder and a decoder. The encoder receives text information that includes a designation of a place, a first image that has been captured by an imaging device and includes the place, and a second image that is segmented into regions by identical object in the first image as input and outputs trimodal features that have been generated to include image features of the captured first image, image features of the second image that is segmented into regions, and language features of the text information. The decoder uses the trimodal features to output a region of the first image that corresponds to the designation of the place in the text information.

IPC Classes  ?

• G06N 3/0455 - Auto-encoder networksEncoder-decoder networks

Abstract

The purpose of the present invention is to provide a detection device that can detect a nucleic acid without depending on the skill or the like of a user, a detection method that uses the detection device, and a heating device that heats the detection device.　This detection device (1) detects an amplified nucleic acid generated from a target nucleic acid included in a sample and has a sample placement member (22) at which the sample is placed, a test piece (29) used for detection of the amplified nucleic acid, amplification members (50, 51, 52, 53) to which is fixed a reagent used to generate the amplified nucleic acid from the target nucleic acid, and supply paths (19, 25, 26, 27, 28) that supply the amplified nucleic acid toward the test piece, the amplification members being provided at the supply paths.

IPC Classes  ?

• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

According to the present invention, intracerebral amyloid-β lesions are detected noninvasively and at low cost. An intracerebral amyloid-β lesion estimation device according to one embodiment of the present invention comprises an estimation model which outputs the presence or absence of an amyloid-β lesion in the brain when information pertaining to blood is input, and also comprises an information acquisition unit that acquires information pertaining to the blood of a subject, an estimation unit that inputs, to the estimation model, the acquired information pertaining to the blood of the subject, and estimates the presence or absence of an amyloid-β lesion in the brain of the subject, and an estimation result output unit that outputs information pertaining to the estimated presence or absence of an amyloid-β lesion in the brain of the subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided are: a fluorine-containing amorphous carbon film which has characteristics of hard coating, antireflection, and antifouling; and a method for producing the same. This fluorine-containing amorphous carbon film is a monolayer film that is composed of carbon, fluorine, and oxygen. The average fluorine content in the film thickness direction is 30% by atom to 40% by atom inclusive, the average oxygen content in the film thickness direction is 5% by atom to 20% by atom inclusive, and the remainder is made up of carbon atoms. With respect to this fluorine-containing amorphous carbon film, a substrate is located in a chamber, and a starting material gas which is represented by a chemical formula that is composed only of carbon and fluorine, and an inert gas for diluting the starting material gas are introduced into the chamber, so that a fluorine-containing amorphous carbon film is formed on the substrate under plasma generation. The mixing ratio of the inert gas into the starting material gas is set to be larger than 1/4 but smaller than 11/1 in terms of the flow rate ratio into the chamber.

IPC Classes  ?

• G02B 1/14 - Protective coatings, e.g. hard coatings
• C03C 17/22 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with other inorganic material
• C23C 16/26 - Deposition of carbon only
• G02B 1/11 - Anti-reflection coatings
• G02B 1/18 - Coatings for keeping optical surfaces clean, e.g. hydrophobic or photo-catalytic films

Abstract

The present invention addresses the problem of providing a method for identifying a candidate cancer patient for anti-PD-1 antibody therapy who exhibits responsiveness to a first anti-PD-1 antibody dose and demonstrates responsiveness to continuous administration of second and subsequent doses, and who experiences less of a burden therefrom.　The present invention is a method for identifying a candidate cancer patient X who is responsive to an anti-PD-1 antibody therapy, said method comprising a step 1 for measuring the mRNA expression level of FGFBP2 in a peripheral blood mononuclear cell of a cancer patient, and a step 2 for comparing the mRNA expression level of the FGFBP2 with a prescribed cut-off value, and being configured in a manner such that the prescribed cut-off value being exceeded by the mRNA expression level of the FGFBP2 demonstrates that the cancer patient is a candidate cancer patient X for administration of a first anti-PD-1 antibody dose.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A control system includes a master device, a slave device, and a control device. Furthermore, the control device includes a tactile force transmission unit and a mode setting unit. The tactile force transmission unit controls tactile force transmission in the master device and the slave device. The mode setting unit changes an amplification factor of force transmitted from the slave device to the master device in a specific section in which a moving element of the slave device moves on the basis of a physical quantity in the moving element of the slave device.

IPC Classes  ?

• B25J 13/08 - Controls for manipulators by means of sensing devices, e.g. viewing or touching devices
• A61B 34/37 - Leader-follower robots

Abstract

To provide a method and a device for producing formic acid.　Provided are a method and a device for producing formic acid by using a conductive diamond electrode and electrolytically reducing carbon dioxide in a single-chamber electrolytic cell.

IPC Classes  ?

• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 3/26 - Reduction of carbon dioxide
• C25B 9/15 - Flow-through cells
• C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form

Abstract

A method for producing a metabolically activated liver organoid, said method comprising a step for culturing primary hepatocytes or hepatocyte-like cells in a differentiation culture medium to obtain a metabolically activated liver organoid, wherein the differentiation culture medium contains: one or two types of agonist selected from the group consisting of growth hormone receptor agonists and prolactin receptor agonists; and a glucocorticoid receptor agonist.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

The present invention assists diagnosis of atrial septal defect. A program according to one embodiment of the present invention causes an estimation device to function as: an electrocardiogram acquisition unit that acquires an electrocardiogram of a patient; an electrical potential data acquisition unit for acquiring, from the electrocardiogram of the patient, time-series data of the electrical potential serving as the source of the electrocardiogram of the patient; an estimation unit for inputting the time-series data of the electrical potential serving as the source of the electrocardiogram of the patient into an estimation model for estimating, from time-series data of the electrical potential serving as the source of an electrocardiogram of a subject, the probability that the subject has atrial septal defect, and outputting the probability that the patient has atrial septal defect; and a display unit for displaying the probability that the patient has atrial septal defect.

IPC Classes  ?

• A61B 5/346 - Analysis of electrocardiograms

Abstract

A magnetic detector (1) comprises: a diamond substrate (10) having an NV center (11); a transparent first substrate (13) on which the diamond substrate is disposed; a radiating body (24) provided on a surface of the first substrate (13) or on the surface of the diamond substrate (10) that is opposite from the surface on which the NV center (11) is provided; and a second substrate (15) which has an opening (16) and on which the first substrate (13) is disposed. The diamond substrate (10) is at least partially exposed through the opening (16).

IPC Classes  ?

• G01R 33/20 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance
• G01N 24/00 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects

Abstract

Provided is a method for producing microglia, including: Step (S1) of inducing differentiation of hemangioblasts to obtain microglial progenitor cells; and Step (S2) of inducing differentiation of the microglial progenitor cells to obtain microglia, in which, in the step of obtaining microglial progenitor cells, expression of PU.1 transcription factor encoded by an exogenous gene is induced, and culture is carried out in the presence of FGF2, SCF, IL-3, IL-6, VEGF, and Wnt inhibitor.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided is an antibacterial composition against a second bacterium that consumes gluconic acid, such as inflammation-inducing bacteria and drug-resistant bacteria, the composition containing, as an active ingredient, a first bacterium that consumes gluconic acid.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 31/04 - Antibacterial agents
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12N 1/20 - BacteriaCulture media therefor

Abstract

An operational data management system includes an operational data acquisition unit, a tag assigner, and a database management unit. The operational data acquisition unit acquires, as operational data, time-series control parameters used to transmit force tactile sensation between devices. The tag assigner assigns, as identification information, information related to operation content implemented by the operational data to the operational data acquired by the operational data acquisition unit. The database management unit accumulates a plurality of pieces of operational data assigned identification information by the tag assigner, and manages the operational data so that desired operational data is searchable from the accumulated plurality of pieces of operational data based on the identification information.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• B25J 13/08 - Controls for manipulators by means of sensing devices, e.g. viewing or touching devices

Abstract

This magnetic field detection device (1) comprises: a diamond substrate (10) which has an NV center (11); a light-emitting element (12) which irradiates the diamond substrate (10) with green light; a light reception element (13) which receives red light generated by inputting the green light to the diamond substrate (10); a first radiation body (22) which applies a microwave to a circuit-to-be-measured (100); and a second radiation body (24) which applies the microwave to the NV center (11) of the diamond substrate (10), wherein a current is excited in the circuit-to-be-measured (100) by applying the microwave to the circuit-to-be-measured (100) by means of the first radiation body (22), and a magnetic field generated from the circuit-to-be-measured (100) is measured by applying the microwave to the NV center (11) by means of the second radiation body (24).

IPC Classes  ?

• G01R 33/20 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance
• G01N 24/00 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
• G01R 33/10 - Plotting field distribution
• G01R 33/032 - Measuring direction or magnitude of magnetic fields or magnetic flux using magneto-optic devices, e.g. Faraday

Abstract

Provided is a compound of formula (I) (in the formula R1, R2, R3, R4, R5, X, m, s, t, A, L, and Y- are as disclosed in the specification).

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups
• G01N 21/64 - FluorescencePhosphorescence

Abstract

A technology of the present disclosure makes it possible to use a reusable object to train a model and grip various vulnerable objects.　This control device uses a plurality of reusable objects to acquire, as training data, observed values in a prescribed breaking process of each of the objects, and uses the training data to apply a machine-learning method corresponding to domain generalization through meta-learning and train an estimation model for estimating timing at which a prescribed action occurs on a target object.

IPC Classes  ?

• B25J 15/08 - Gripping heads having finger members
• B25J 9/16 - Programme controls
• G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
• G06N 3/0455 - Auto-encoder networksEncoder-decoder networks
• G06N 3/0985 - Hyperparameter optimisationMeta-learningLearning-to-learn
• G06N 20/00 - Machine learning

Abstract

A light intensity measurement system includes a light source unit configured to emit coherent light to aqueous humor of a subject eye, a polarization control unit that is arranged between the light source unit and the subject eye, and configured to control a polarization state of the coherent light, and a measurement unit configured to measure light intensity of scattered light in the aqueous humor of the coherent light. With this configuration, a light intensity measurement system that can non-invasively measure the concentration of substances contained in aqueous humor of a subject eye is provided.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
• G01N 21/47 - Scattering, i.e. diffuse reflection

Abstract

A processing apparatus includes: a processing portion that interpolates, when at least one of two-dimensional image information and three-dimensional sensor information that are input at an arbitrary time is missing, the missing two-dimensional image information or the missing three-dimensional sensor information and outputs an object detection result based on the interpolated two-dimensional image information and the interpolated three-dimensional sensor information to an object-tracking apparatus, wherein the processing portion interpolates the missing one of the two-dimensional image information and the three-dimensional sensor information with conversion of another of the two-dimensional image information and the three-dimensional sensor information, or interpolates the two-dimensional image information or the three-dimensional sensor information at a missing time with estimation based on two-dimensional image information or three-dimensional sensor information at another time.

IPC Classes  ?

• G06V 10/20 - Image preprocessing
• G06T 7/277 - Analysis of motion involving stochastic approaches, e.g. using Kalman filters
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods

Abstract

Provided is a method for growing a multi-layered graphene layer on a substrate in simple steps, while suppressing influence on the substrate. This graphene growth method involves: forming, on a substrate, a single layer of a carbon-containing metal thin film including carbon in an amount exceeding the solid solution limit such that the content of the carbon based on the carbon-containing metal thin film becomes 3%-98% in terms of molar ratio; subjecting the carbon-containing metal thin film to thermal treatment without introducing carbon raw material gas using organic molecules to produce graphene while also separating metal included in the carbon-containing metal thin film; and removing the separated metal after the completion of the thermal treatment.

IPC Classes  ?

• C01B 32/184 - Preparation
• G02B 6/13 - Integrated optical circuits characterised by the manufacturing method

Abstract

The present disclosure provides a pharmaceutical for treating or preventing pemphigus. More specifically, the present disclosure provides a pharmaceutical composition for treating or preventing pemphigus, the composition containing, as an active ingredient, an induced regulatory T cell having at least one characteristic among CTLA4 positive, NT5E positive, ITGAE (CD103) positive, AREG positive, CD172g positive, and CD26 positive.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 17/00 - Drugs for dermatological disorders
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention is to provide a means for promoting muscle regeneration from muscle damage. The present invention is to provide a means for promoting muscle regeneration from muscle damage. According to the present invention, the muscle regeneration from muscle damage is promoted by using a compound having histamine H receptor agonist activity (except for histamine) or a salt thereof is used as an active ingredient.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system